The guanine nucleotide exchange factor Rin-like is a repressor for renal uric acid excretion in human and mouse
- 23 September 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (868)
Abstract
The prevalence of hyperuricemia (HUA) is increasing annually and now affects ∼14% of the population. Uric acid (UA) is the end product of purine metabolism in humans. Either increased production or reduced excretion of UA can induce HUA. Here, we identified RAS and RAB interactor–like (RINL) as a regulator of renal UA excretion and conducted a screen for compounds capable of lowering serum UA concentrations. We found that the human RINL ( hRINL ) Pro 139 →Ser (P139S) mutation was pathogenic for HUA in a familial pedigree. As a guanine nucleotide exchange factor, RINL activated RAB5C in renal tubular epithelial cells. Activated RAB5C promoted the endocytosis and lysosomal degradation of the UA transporter ATP-binding cassette subfamily G member 2, thereby inhibiting renal UA excretion and contributing to the development of HUA. The hRINL (P139S) mutation inhibited proteasome-mediated degradation of hRINL in renal tubular epithelial cells, causing its accumulation, and the homologous mouse RINL ( mRINL ) Pro 140 →Ser (P140S) mutation up-regulated mRINL in mouse kidneys, indicating a gain-of-function mutation. We screened a library of 1500 natural products for RINL inhibitors and, after experimental validation, found that tetrahydrocurcumin bound to RINL and promoted its degradation, thereby ameliorating HUA induced by potassium oxonate treatment, uricase knockout, or secondary to severe malaria and chronic kidney disease in mice. These findings establish RINL as a repressor of UA excretion in both humans and mice and suggest that targeted degradation of RINL represents a promising strategy for HUA treatment.Keywords
Funding Information
- National Natural Science Foundation of China (32571506)
- National Natural Science Foundation of China (22376174)
- Natural Science Foundation of Fujian Province, China (2025J010004)
This publication has 112 references indexed in Scilit:
- Metabolomic and Cellular Mechanisms of Drug‐Induced Ototoxicity and Nephrotoxicity: Therapeutic Implications of Uric Acid ModulationAdvanced Science, 2025
- The Gut Microbiome in Hyperuricemia and GoutArthritis & Rheumatology, 2025
- Slow Metabolism–Driven Amplification of Hepatic PPARγ Agonism Mediates Benzbromarone‐Induced Obesity‐Specific Liver InjuryAdvanced Science, 2024
- Intestine‐Targeted Explosive Hydrogel Microsphere Promotes Uric Acid Excretion for Gout TherapyAdvanced Materials, 2023
- Superiority of low‐dose benzbromarone to low‐dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et alArthritis & Rheumatology, 2023
- Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian RandomizationArthritis & Rheumatology, 2021
- Dietary and Lifestyle-Centered Approach in Gout Care and PreventionCurrent Rheumatology Reports, 2021
- Inhibiting PNP for the therapy of hyperuricemia in Lesch–Nyhan disease: Preliminary in vitro studies with analogues of immucillin‐GJournal of Inherited Metabolic Disease, 2019
- Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney diseaseClinical and Experimental Nephrology, 2013
- Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trialArthritis Care & Research, 2008